Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma Journal Article
| Authors: | Khashab, T.; Hagemeister, F.; Romaguera, J. E.; Fanale, M. A.; Pro, B.; McLaughlin, P.; Rodriguez, M. A.; Neelapu, S. S.; Fayad, L.; Younes, A.; Feng, L.; Vega, F.; Kwak, L. W.; Samaniego, F. |
| Article Title: | Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma |
| Abstract: | In a prospective phase II trial, pentostatin combined with cyclophosphamide and rituximab (PCR) induced strong responses and was well-tolerated in previously untreated patients with advanced-stage, indolent non-Hodgkin lymphoma (iNHL). After a median patient follow-up of more than 108 months, we performed an intent-to-treat analysis of our 83 participants. Progression-free survival (PFS) rates at 108 months for follicular lymphoma (FL), marginal zone lymphoma (MZL) and small lymphocytic lymphoma (SLL) were 71%, 67% and 15%, respectively, and were affected by clinicopathological characteristics. Ten-year PFS rates for those with beta-2-microglobulin levels <2·2 and ≥2·2 mg/l prior to treatment were 71% and 21%, respectively. Patients without bone marrow involvement had 10-year PFS rates of 72% vs. 29% for those with involvement. At time of analysis, the median overall survival (OS) had not been reached. The OS rate was 64% at 10 years and differed significantly based on histology: 94% for FL, 66% for MZL and 39% for SLL. Long-term toxicities included 18 (21·7%) patients with second malignancies and 2 (2·4%) who developed myelodysplastic syndrome after receiving additional lines of chemotherapy. Our 10-year follow-up analysis confirms that PCR is an effective, robust and tolerable treatment regimen for patients with iNHL. © 2019 British Society for Haematology and John Wiley & Sons Ltd |
| Keywords: | adult; cancer survival; controlled study; human tissue; aged; middle aged; major clinical study; overall survival; drug tolerability; histopathology; neutropenia; drug efficacy; drug safety; treatment duration; rituximab; prospective study; polymerase chain reaction; melanoma; progression free survival; multiple cycle treatment; phase 2 clinical trial; basal cell carcinoma; cyclophosphamide; renal cell carcinoma; hodgkin disease; myelodysplastic syndrome; nonhodgkin lymphoma; breast carcinoma; b cells; follicular lymphoma; marginal zone lymphoma; pentostatin; hematologic disease; cystadenocarcinoma; multiple organ failure; single blind procedure; non small cell lung cancer; institutional review; lymphomas; diffuse large b cell lymphoma; very elderly; human; priority journal; article; lymphocytic lymphoma; squamous cell skin carcinoma; purine analogues; indolent nonhodgkin lymphoma |
| Journal Title: | British Journal of Haematology |
| Volume: | 185 |
| Issue: | 4 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2019-05-01 |
| Start Page: | 670 |
| End Page: | 678 |
| Language: | English |
| DOI: | 10.1111/bjh.15814 |
| PUBMED: | 30820940 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
